Tumor-Derived Extracellular Vesicles in Plasma for Predicting Anti-PD-1 Antibody Efficacy in Non-Small Cell Lung Cancer.
Tiny tumor particles in blood may predict which lung cancer patients will respond to immunotherapy before treatment starts.
Kinoshita T et al. evaluated plasma-derived tumor extracellular vesicles (tEVs) as a non-invasive biomarker for predicting the efficacy of anti-PD-1 antibodies in non-small cell lung cancer patients. The study identified specific tEV signatures associated with ICI response, suggesting utility for patient selection and treatment monitoring in immunotherapy.
What the study was
- Study design
- Exploratory biomarker study (plasma-based)
- Population
- Non-small cell lung cancer patients receiving anti-PD-1 immunotherapy
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Cancer science
Why it surfaced
Plasma EVs as ICI response biomarkers in NSCLC is an emerging and clinically significant area; study directly relevant to watchlist liquid biopsy and immunotherapy topics. Exploratory stage; sample size unknown.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.